<DOC>
	<DOCNO>NCT02036580</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability multiple-doses tralokinumab Japanese patient Idiopathic Pulmonary Fibrosis .</brief_summary>
	<brief_title>D2212C00002 J-Phase II Study</brief_title>
	<detailed_description>This phase II , multicenter , blind within cohort , dose-escalation study evaluate safety tolerability two ascend dos tralokinumab Japanese patient age ≥ 50 year mild moderate Idiopathic Pulmonary Fibrosis .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Confirmed IPF diagnosis ≤ 5 year prior Visit 1 ( screen ) . Confirmation diagnosis IPF Mild moderate IPF include follow Visit 1 1 . FVC ≥ 50 % ≤ 90 % predict normal 2 . Partial pressure oxygen arterial blood ( PaO2 ) ≥ 55 mmHg room air , oxygen saturation pulse oximetry ( SpO2 ) ≥ 90 % room air rest 3 . Hemoglobincorrected diffusion capacity carbon monoxide ( DLCO ) ≥ 30 % ≤ 90 % predict normal History clinically significant environmental exposure ( eg , domestic occupational ) know cause pulmonary fibrosis Diagnosis connective tissue disease drug toxicity likely cause interstitial disease A suspect IPF exacerbation fully resolve treatment complete ≤ 14 day prior Visit 1 A suspected IPF exacerbation screen period A FEV1/FVC ratio &lt; 0.70 time Visit 1 ( postbronchodilator ) The extent emphysema HRCT great extent fibrosis</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Japan</keyword>
	<keyword>Phase2</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Idiopathic Pulmonary Fibrosis</keyword>
	<keyword>IPF</keyword>
	<keyword>CAT-354</keyword>
	<keyword>Tralokinumab</keyword>
</DOC>